NCT05075538终止4 期
COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
适应症
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 152
- 试验地点
- 4
- 主要终点
- Humoral immune response against SARS-CoV-2 after the last dose of a mRNA anti-SARS-CoV-2 vaccine (Baseline assessment)
研究概览
简要总结
This trial aims to measure the humoral and adaptive immune response in patients with cancer diagnosis undergoing mRNA vaccination against SARS-CoV-2 and assess its efficacy in preventing COVID-19.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old
- •ECOG performance status ≤ 2
- •Subjects with histologically or cytologically confirmed cancer diagnosis (invasive solid tumour or haematological malignancy)
- •undergoing active systemic cancer treatment at the time of the last dose (before ICF signature) of the anti-SARS-CoV-2 mRNA vaccine (such as chemotherapy, immunotherapy, targeted agents, endocrine therapy) in non-metastatic/curative setting or in metastatic/palliative setting
- •or undergoing follow-up after confirmed cancer complete remission without active cancer treatment for the last 12 months at the time of the last dose (before ICF signature ) of the anti-SARS-CoV-2 mRNA vaccine.
- •Life expectancy > 6 months
- •Subjects who received at least 2 doses of mRNA platform vaccination against SARS-CoV-2 as per local guidelines, with the last dose being given between 3 and 12 months prior to baseline assessment.
- •Urine/serum pregnancy test negative for all female subjects of childbearing potential within 7 days prior to subject enrolment.
- •Signed Informed Consent form (ICF) obtained prior to any study related procedure
- •Subject is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations.
排除标准
- •Known pregnant and/or lactating women.
- •Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study.
- •Subjects with active diagnosis of acute leukaemia.
- •Subjects treated with bone marrow transplant < 90 days before received vaccination against SARS-CoV-
- •Subjects with a known history of HIV infection.
- •COVID-19 infection in the last 28 days prior to subject enrolment.
- •Subjects receiving prolonged and/or high doses of systemic immunosuppressive therapies including corticosteroids during the last 28 days before receiving first dose of vaccination against SARS-CoV-2 and up to subject enrolment.
- •Subjects who, for any reason, did not receive the 2nd dose of the anti-SARS-CoV-2 mRNA vaccine.
- •Subjects that received the 3rd dose of anti-SARS-CoV-2 mRNA vaccine prior to study entry. Exclusion criterion number 9 is only applicable for previous versions of the protocol and is not applicable from protocol version 3.0 and subsequent versions.
- •Subject that received any dose of non-mRNA anti-SARS-CoV-2 vaccine platform.
- •Subject with a known or suspected history of severe adverse reactions associated with a vaccine and/or with severe allergic reaction to vaccine components or anaphylaxis in the past.
- •Subjects who planned to receive any other licensed vaccines for other indications within 28 days prior to the first booster dose after ICF signature or who are planning to receive any other vaccine up to 14 days after the first booster dose of the mRNA anti-SARS-CoV-2 vaccine after ICF signature (28 days for live attenuated vaccines). For influenza vaccination, a shorter interval or simultaneous administration is acceptable.
- •Subjects who have planned to receive a booster dose after ICF signature but before the baseline assessment
- •Subjects who received COVID-19 pre-exposure prophylactic monoclonal antibodies or who have been treated with anti-SARS-CoV-2 monoclonal antibodies or COVID-19 convalescent plasma during the last 6 months before ICF signature.
结局指标
主要结局
Humoral immune response against SARS-CoV-2 after the last dose of a mRNA anti-SARS-CoV-2 vaccine (Baseline assessment)
时间窗: 3 to 12 months after the last dose
Rate of humoral immune response against SARS-CoV-2 between 3 and 12 months after the last dose (before ICF signature) of a mRNA anti-SARS-CoV-2 vaccine (baseline assessment)
次要结局
- Humoral immune response against SARS-COV-2(at 6 months (+/- 4 weeks) after the baseline assessment or at 6 months (+ 4 weeks/- 8 weeks) after the first booster after ICF signature, if a booster dose of the vaccine is administered during the study per local / national health policy guidelines.)
- Humoral immune response against SARS-COV-2 by cohort(3 to 12 months after the last dose before ICF signature; and 6 months (+/- 4 wks) after baseline assessment or 6 months (+ 4 wks/-8 wks) after the first booster after ICF signature if a booster dose is administered during the study)
- Safety of booster dose(s) of mRNA anti-SARS-CoV-2 vaccine received after ICF signature(During the 30 days following the administration of the booster received during the study period (if any))
- Rate of asymptomatic subjects with SARS-CoV-2 positive test during the study(Retrospectively collected at each visit: at baseline assessment, pre-boosting (within 2 wks before 1st booster dose after ICF signature), post-boosting (2 wks after this booster); and 6 months after this booster OR after baseline assessment if no booster)
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
COVID-19 :Immune response in patients with cancer undergoing vaccination against SARS-CoV-2adult cancer patientsMedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003710-39-BEINSTITUT JULES BORDET440
进行中（未招募）
1 期
COVID-19: Immune response in patients with cancer undergoing mRNA vaccination against SARS-CoV-2. I-SPARC studyadult cancer patientsMedDRA version: 23.1Level: PTClassification code 10084457Term: COVID-19 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003710-39-PTINSTITUT JULES BORDET525
已完成
不适用
Host Immune Response to Novel RNA COVID-19 VaccinationCOVID-19 VaccineCancerNCT04784689The University of Texas Health Science Center at San Antonio50
已完成
不适用
Efficacy and Safety of COVID-19 Vaccine in Cancer PatientsCOVID-19 InfectionMalignant Solid NeoplasmNCT04865133Mayo Clinic89
已完成
不适用
Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology PatientsCovid19CancerNCT04854980University of Rochester8